Source: Virtual Congress 2020 – Interstitial lung diseases
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
P. Janowiak (Gdansk, Poland). Granulomatous lung disease in lymphoma patient after rituximab treatment. Virtual Congress 2020 – Interstitial lung diseases

Member's Comments

No comment yet.

Related content which might interest you: Interstitial lung disease and fever as main manifestations of angiotropic lymphoma Source: Eur Respir J 2001; 18: Suppl. 33, 528s Year: 2001 Rituximab in the treatment of refractory pulmonary sarcoidosis Source: Eur Respir J 2014; 43: 1525-1528 Year: 2014 Endobronchial primary pulmonary non-Hodgkin lymphoma development in a patient with rheumatoid arthritis Source: Eur Respir J 2001; 18: Suppl. 33, 398s Year: 2001 Rituximab for the treatment of chronic hypersensitivity pneumonitis Source: International Congress 2015 – Interstitial lung diseases I Year: 2015 Rituximab therapy for interstitial lung disease in patients with antisynthetase syndrome Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease Year: 2013 Rituximab therapy in a patient with steroid-refractory bird fancier's lung Source: International Congress 2019 – CCC Interstitial lung diseases Year: 2019 Rituximab-induced lung disease: a systematic literature review Source: Eur Respir J 2010; 35: 681-687 Year: 2010 Primary pulmonary non-Hodgkin's lymphoma [NHL] and advanced NHL with pulmonary involvement -rare entity and difficult diagnosis Source: Eur Respir J 2002; 20: Suppl. 38, 467s Year: 2002 Clinical and radiological correlation of pulmonary complications in CHOP versus rituximab-CHOP regimen treated non-Hodgkin’s lymphoma in Thailand Source: International Congress 2017 – Rare diseases Year: 2017 Treatment of relapsed hydatid disease of lungs. Source: Virtual Congress 2020 – Thoracic surgery: lung cancer and infectious disease Year: 2020 Pulmonary toxicity of treatments for leukaemia and lymphoma Source: International Congress 2018 – Respiratory medicine meets hematology Year: 2018 Cyclophosphamide in steroid-refractory hypersensitivity pneumonitis and non-classifiable interstitial lung disease Source: International Congress 2017 – Novel and old entities Year: 2017 Pulmonary non-Hodgkin‘s lymphoma developed during long-term methotrexate therapy for rheumatoid arthritis Source: Annual Congress 2009 - Various diagnostic aspects in lung cancer and rare lung tumours Year: 2009 Diffusion lung capacity changes in Hodgkin lymphoma patients before and after ABVD chemotherapy Source: International Congress 2015 – Lung function: exploring the boundaries of the respiratory system Year: 2015 Pulmonary tuberculosis in hodgkin's disease after high dose chemotherapy Source: Annual Congress 2003 - Clinical aspects of tuberculosis Year: 2003 Primary pulmonary lymphoma Source: Eur Respir J 2002; 20: 750-762 Year: 2002 Efficacy of switching from cyclosporine A to tacrolimus in patients with refractory CTD-ILD Source: International Congress 2016 – Connective tissue disorders Year: 2016 Infliximab: An effective rescue therapy in refractory extra-pulmonary sarcoidosis Source: Annual Congress 2013 –Sarcoidosis and other granulomatosis Year: 2013 Pulmonary function changes during treatment with rituximab in patients with rheumatoid arthritis Source: International Congress 2014 – ILDs: pathogenesis and clinical features Year: 2014 Pneumococcal vaccination in interstitial lung disease patients receiving systemic immunosuppressive treatment Source: International Congress 2017 – Discussion of vaccines, biomarkers and risk factors analysis   Year: 2017